非酒精性脂肪性肝病患者血清OCN、β-CTX和血管紧张素水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2025.03.015

Abstract

Abstract: Objective The aim of this study was to explore implication of serum osteocalcin (OCN), β-I type collagen carboxy-terminal peptide (β-CTX) and angiotensin-II(Ang-II) levels in patients with non-alcoholic fatty liver diseases(NAFLD). Methods 101 patients with NAFLD, including simple fatty liver (SFL) in 32 cases, nonalcoholic steatohepatitis (NASH) in 50 cases and fatty-related liver cirrhosis (LC) in 19 cases, and 53 healthy individuals who underwent for physical examinations were enrolled in our hospital between June 2022 and December 2023, and all received Fibroscan scan for liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). Serum OCN level was detected by ELISA, serum β-CTX level was determined by electrochemiluminescence immunoassay, and serum Ang-II level was measured by using fully automated chemiluminescence instrument. Results CAP in patients with SFL was much higher than in healthy control(P＜0.05), serum ALT and AST levels, as well as LSM and CAP in patients with NASH and with LC were much higher than in patients with SFL or healthy individuals (P＜0.05), and LSM in patients with LC was much higher than in with NASH(P＜0.05); serum OCN and β-CTX levels in patients with NASH were (17.3±6.3)ng/mL and (0.3±0.1)ng/mL, both significantly lower than [ (22.8±6.4)ng/mL and (0.4±0.2)ng/mL, respectively, P＜0.05] in patients with SFL, while serum Ang-Ⅱ level was (2.7±0.5)μg/L, significantly higher than [(2.4±0.4)μg/L, P＜0.05] in patients with SFL; serum Ang-Ⅱ level in patients with LC was (3.0±0.6)μg/L, much higher than in with NASH(P＜0.05); serum OCN and β-CTX levels in 19 patients with advanced liver fibrosis were(16.0±6.9)ng/mL and (0.2±0.1)ng/mL, both significantly lower than [(19.6±6.0)ng/mL and (0.4±0.1)ng/mL, respectively, P＜0.05], while serum Ang-Ⅱ level was (3.1±1.5)μg/L, much higher than [(2.5±0.7)μg/L, P＜0.05] in 31 patients with significant liver fibrosis. Conclusion Abnormal changes of serum OCN, β-CTX and Ang-II levels in patients with NAFLD is common, which might help assess steatosis and fibrosis.

Key words: Non-alcoholic fatty liver diseases, Nonalcoholic steatohepatitis, Liver fibrosis, Osteocalcin, β-I type collagen carboxy-terminal peptide, Angiotensin, Clinical implication

Wang Xintian, Kang Xiaobo, Wu Xia, et al. Changes of serum osteocalcin,β-I type collagen carboxy-terminal peptide and angiotensin levels in patients with non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2025, 28(3): 378-381.

References

[1] Flessa CM, Kyrou I, Nasiri-Ansari N,et al. Endoplasmic reticulum stress and autophagy in the pathogenesis of non-alcoholic fatty liver disease (NAFLD): current evidence and perspectives. Curr Obes Rep, 2021, 10(2):134-161.
[2] Kokkorakis M, Boutari C, Katsiki N,et al. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism, 2023, 147:155664.
[3] Roderburg C, Kostev K, Mertens A,et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer. Gut, 2023, 72(12):2383-2384.
[4] 吴非,郭雯,张群.非酒精性脂肪性肝病患者骨骼肌质量变化研究.实用肝脏病杂志,2023,26(5):646-649.
[5] Wang S, Sun W, Zhou X. Bonemetabolism discrepancy in type 2 diabetes mellitus patients with and without non-alcoholic fatty liver disease. J Clin Densitom, 2022, 25(4):553-558.
[6] Barchetta I, Lubrano C, Cimini FA,et al. Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease. Hepatol Int, 2023, 17(2):357-366.
[7] Fu J, Mu Z, Sun L,et al. Chinese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease have lower serum osteocalcin levels compared to individuals with type 2 diabetes mellitus and no liver disease: a single-center cross-sectional study. J Endocrinol Invest, 2022, 45(12):2275-2282.
[8] Kim KM, Roh JH, Lee S,et al. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep, 2021, 11(1):2884.
[9] Song LN, Liu JY, Shi TT,et al. Angiotensin-(1-7), the product of ACE2 ameliorates NAFLD by acting through its receptor mas to regulate hepatic mitochondrial function and glycolipid metabolism. FASEB J, 2020, 34(12):16291-16306.
[10] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510.
[11] Roderburg C, Krieg S, Krieg A,et al. Non-alcoholic fatty liver disease (NAFLD) and risk of new-onset heart failure: a retrospective analysis of 173,966 patients. Clin Res Cardiol, 2023, 112(10):1446-1453.
[12] 梁小丽,邝继孙,刘秋莉,等.非诺贝特联合热量限制饮食治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究.实用肝脏病杂志,2021,24(1):51-54.
[13] Nabi O, Lapidus N, Boursier J,et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology, 2023, 78(1):272-283.
[14] 朱燕,胡竞成,吴梦娇,等.血清CXC趋化因子配体17与2型糖尿病合并非酒精性脂肪性肝病的相关性研究.中华糖尿病杂志,2024,16(2):214-219.
[15] 黄琦,杨培庆,梅腾悦,等.非酒精性脂肪性肝病患者骨代谢指标的变化.中华骨质疏松和骨矿盐疾病杂志,2021,14(4):368-373.
[16] Xia M, Rong S, Zhu X,et al. Osteocalcin and non-alcoholic fatty liver disease: lessons from two population-based cohorts and animal models. J Bone Miner Res, 2021, 36(4):712-728.
[17] 王冠华,吴林峰,张益明,等.血清t-PINP/β-CTX比值、25(OH)D水平在老年女性分化型甲状腺癌术后防治骨质疏松中的监测价值.中华内分泌外科杂志,2023,17(2):204-208.
[18] Yu C, Guo X, Cui X,et al. Functional food chemical ingredient strategies for non-alcoholic fatty liver disease (NAFLD) and hepatic fibrosis: chemical properties, health benefits, action, and application. Curr Nutr Rep, 2024, 13(1):1-14.
[19] Zaravar F, Tamaddon G, Zaravar L,et al. The effect of aquatic training and vitamin D3 supplementation on bone metabolism in postmenopausal obese women. J Exerc Sci Fit, 2024, 22(2):127-133.
[20] Zhang Q, Jia R, Chen M,et al. Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and hepatic stellate cells. J Gastroenterol Hepatol, 2023, 38(3):441-450.
[21] Drobinska N, Abrahamovych O, Abrahamovych M,et al. Characteristics of calcium-phosphorus metabolism and bone turnover indicators in patients with liver cirrhosis and their diagnostic value for assessing bone structures disorder. Georgian Med News, 2023, (334):41-48.
[22] Panigrahi MK, Anirvan P. Using angiotensin-converting enzyme inhibitors to prevent liver-related events in NAFLD-revisiting the renin-angiotensin-aldosterone system pathways. Hepatology, 2022, 76(2):E32-E33.
[23] Machado AS, Oliveira JR, Lelis DF,et al. Oral probiotic bifidobacterium longum supplementation improves metabolic parameters and alters the expression of the renin-angiotensin system in obese mice liver. Biol Res Nurs, 2021, 23(1):100-108.
[24] Burra P, Bizzaro D, Gonta A,et al. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int, 2021, 41(8):1713-1733.

Changes of serum osteocalcin,β-I type collagen carboxy-terminal peptide and angiotensin levels in patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Yu, Liu Jie, Fan Jianmin, et al. Sound touch elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(3): 342-345.
[2]	Zeng Ai, Wang Cong, Li Min, et al. Diagnostic performance of shear wave elastography and APRI combination in predicting significant liver fibrosis in patients with type 2 diabetes mellitus and NAFLD [J]. Journal of Practical Hepatology, 2025, 28(3): 382-385.
[3]	Liu Qianqian, Duan Zhijiao, Chen Ping. Non-invasive assessment of liver fibrosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 477-480.
[4]	Zhu Tingting, Chen Yiyun, Xie Fanci, et al. Non-invasive assessment of liver fibrosis reverse in patients with chronic liver diseases [J]. Journal of Practical Hepatology, 2025, 28(2): 169-172.
[5]	Yu Kai, Mei Yunhua, Zhou Jinrong, et al. Ultrasonic transient elastography in predicting liver fibrosis in patients with chronic hepatitis B and liver steatosis [J]. Journal of Practical Hepatology, 2025, 28(2): 190-193.
[6]	Wang Xiaoyan, Cui Wenxing, Chen Chao. Controlled attenuation parameter, liver stiffness measurement and total adipose tissue in screening patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(2): 198-201.
[7]	Wang Changhe, Zhu Xuan, Deng Jing, et al. Preliminary diagnosis of liver fibrosis by shear wave elastography in combination with AAR, APRI and FIB-4 in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(1): 32-35.
[8]	Hu Yu, Wang Jinghui, Wang Yao. Combination of sound palpation tissue quantification and FIB-4 index and AST/ALT ratio in evaluation of liver fibrosis in patients with hepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 36-39.
[9]	Ma Min, Xu Qiaoyun. Clinical implications of serum arginase-1 levels and apolipoprotein B /apolipoprotein A1 ratio in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 52-55.
[10]	Shen Yue, Zhu Ning, Wang Hai. Diagnostic performance of FibroTouch parameters in the diagnosis of non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 60-63.
[11]	Wang Wendong, Liang Maoquan, Liu Yuyan. Portal vein hemodynamic changes in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portal shunting and partial splenic artery embolization [J]. Journal of Practical Hepatology, 2025, 28(1): 120-123.
[12]	Jiang Shetian, Yan Wei, Zhao Lei, et al. Diagnostic performance of ultrasound virtual touch tissue quantification and serum liver fibrosis markers in predicting liver fibrosis in patients with hepatic schistosomiasis [J]. Journal of Practical Hepatology, 2025, 28(1): 124-127.
[13]	Jia Jihui, Zhang Yizhi, Lin Jing, et al. Down-regulation of hepatic SREBP1 and PPAR-γ expression by naringin in mice with high-fat diet-induced NAFLD [J]. Journal of Practical Hepatology, 2024, 27(6): 816-819.
[14]	Zhang Tianting, Xu Jing, Jiang Zhengwei, et al. Improvement of liver fibrosis in patients with chronic hepatitis B after tenofovir alafenamide fumarate antiviral and herbal medicine anti-fibrotic therapy [J]. Journal of Practical Hepatology, 2024, 27(6): 820-823.
[15]	Zhou Jun, Zhang Zhongxin, Xu Haiyan. Assessment of significant liver fibrosis by visual instantaneous elastography and acoustic palpation elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(6): 832-835.